Acetyl-L-Carnitine: Pain Relief in Diabetes, Harm During Chemotherapy

What acetyl-L-carnitine is

Acetyl-L-carnitine, often called ALCAR, is one form of carnitine, a substance the body uses to carry long-chain fatty acids into mitochondria, the structures inside cells that produce usable energy. The liver, kidneys, and brain make carnitine, and meat adds more: a 3-ounce beef steak has about 42 to 122 mg. Healthy people, including vegans, make enough on their own.

Supplements come as 250 to 600 mg capsules and as powder. There is no official daily amount.

People take it for nerve pain, memory, mood, energy, and weight loss. In diabetic nerve damage, it eased pain but did not improve nerve-conduction tests, which measure how fast and strongly nerves carry signals. In a large chemotherapy trial it made nerve damage worse. Memory findings have been inconsistent. Mood studies and small fatigue trials offer possible benefits in selected clinical settings; the details matter.

What acetyl-L-carnitine does in your body

Carnitine helps move long-chain fatty acids into mitochondria, where cells can break them down for energy. This transport happens across mitochondrial membranes inside cells; it is not a process that directly pulls stored body fat into a muscle.

Acetyl-L-carnitine is carnitine carrying a small chemical unit called an acetyl group. Transferring an acetyl group onto carnitine frees another carrier, coenzyme A, for further reactions that process fuel. The transfer is reversible, allowing cells to balance acetyl groups and free coenzyme A as fuel use changes. This physiological review describes the reaction^[1]. Acetyl-L-carnitine therefore belongs to a wider carnitine system rather than being a separate source of energy.

Healthy adults usually make the carnitine they need; production or transport disorders are separate clinical conditions. ^[2]

What people take acetyl-L-carnitine for

About the evidence assessments: “Moderate” means persuasive evidence with important uncertainties. “Review pending” means we have not finished assessing the research; it is a review status rather than a strength rating. The findings and remaining questions are described below.

Most people do not need it. The best-supported use is painful nerve damage from diabetes, where trials found less pain, though not better nerve function; that is a conversation for your doctor, alongside standard care. The mood evidence is more mixed than a simple recommendation to add it to an antidepressant. Small fatigue studies concern people with multiple sclerosis or older adults with persistent symptoms.

Do not take it to prevent nerve damage from chemotherapy. In a large trial of women receiving taxane chemotherapy, such as paclitaxel or docetaxel, for breast cancer, nerve damage was worse on ALCAR, most clearly through 52 weeks.

When to ask a doctor before taking acetyl-L-carnitine

• You are having chemotherapy, or will soon, and want to take it for any reason. It worsened chemotherapy nerve damage in a large trial.
• You have a seizure disorder. Carnitine supplements can trigger seizures in people who have them.
• You have kidney failure. People on dialysis can run low in carnitine, but supplements can also cause muscle weakness in kidney failure, so the decision belongs with your kidney doctor.
• You take anti-seizure medicine, or long courses of antibiotics to prevent urinary infections. Some anti-seizure drugs and uncommon pivalate antibiotics, including pivampicillin, lower the body’s carnitine. Ask a pharmacist to check the exact medicine name and whether the carnitine change needs treatment.
• You are pregnant or breastfeeding. We found no studies of supplement amounts during pregnancy or breastfeeding.

Can I be low in carnitine?

Low carnitine is uncommon in healthy people. A vegan diet supplies little carnitine, but the body usually makes enough. Low levels occur mainly with some genetic conditions, kidney failure treated with dialysis, and certain medicines, and a doctor can measure carnitine in the blood when one of those causes is suspected.

A free-and-total carnitine blood test can help investigate a suspected deficiency. “Free” means carnitine without an attached chemical group; “total” also includes carnitine carrying those groups, such as acetyl-L-carnitine. A high result may reflect recent meat consumption or carnitine supplementation rather than a disorder. A low or otherwise abnormal result does not by itself distinguish an inherited problem with carnitine transport from a secondary cause, such as another metabolic condition, kidney disease or certain medicines; the clinician may need further testing and the clinical history to find the cause. ^[3]

Before the test if you already supplement

For this blood test, Mayo Clinic Laboratories^[3] gives no fixed supplement-stop interval. Tell the specialist that you take acetyl-L-carnitine or L-carnitine and give the dose and last dose. Ask whether the sample should be collected before the next dose. A test used to follow carnitine treatment may intentionally measure your level while taking it; do not assume you need to stop prescribed carnitine for a period before testing.

Is acetyl-L-carnitine the same as L-carnitine, and which is better?

They are related but not the same. Acetyl-L-carnitine carries an extra acetyl group; L-carnitine is the basic form. The nerve trials discussed here used acetyl-L-carnitine, and the heart-risk research on TMAO, a substance produced from carnitine with the help of gut bacteria, used L-carnitine. The depression literature also includes other preparations, as the review comparison below explains. The studies discussed here do not establish that one is better than the other for nerve pain, depression or memory.

What to pay attention to on the label

Acetyl-L-carnitine is sold as capsules and powder. The numbers to find are the milligrams of acetyl-L-carnitine per capsule and the number of capsules in a serving.

Which number on the label is the amount?

Look for acetyl-L-carnitine in milligrams on the Supplement Facts panel. Labels often name the salt it comes from, acetyl-L-carnitine HCl, in brackets; the labels we looked up give the amount as acetyl-L-carnitine, which is the number to compare with trial doses. Labels in the NIH Dietary Supplement Label Database include a 500 mg capsule and a product sold as “1,200 mg” that gives that amount per two capsules, so each capsule is 600 mg.

Misleading labels

Carnitine blends

Some products mix acetyl-L-carnitine with L-carnitine or other forms without saying how much of each. A total “carnitine” amount can make the whole serving appear relevant to nerve research even though those trials used acetyl-L-carnitine alone and its share of the blend is hidden.

Confusing servings and items per serving

Some manufacturers put 180 capsules on the front, and the back says 3 capsules per serving and 60 servings. The amount on the Supplement Facts panel is for the whole 3-capsule serving.

Manufacturer claims and the studies they may be based on

A “supports nerve health” line may point to the diabetic nerve trials, where pain improved but nerve function tests did not. A “supports memory” line may point to older dementia trials that a Cochrane review, a systematic summary of trials, did not find convincing. A “supports mood” line may point to small depression trials; their results vary by patient group and by what ALCAR was compared with.

Common Myths about Acetyl-L-carnitine

Does ALCAR help you lose weight?

Fat-burning label claims are not backed by a trial showing that acetyl-L-carnitine causes weight loss in the research we found, and despite comparisons online, it does not work like weight-loss drugs such as Ozempic.

Drawbacks and side effects

Side effects around 3 g a day

There is no official upper limit. At about 3 g a day, carnitine supplements can cause nausea, vomiting, cramps, diarrhea, and a fishy body odor.

Risks tied to a condition or treatment

They can trigger seizures in people with seizure disorders and cause muscle weakness in people with kidney failure.

The most serious finding is from chemotherapy: in a trial of 409 women, 1 g three times a day during taxane chemotherapy made nerve damage worse than placebo, most clearly from 24 to 52 weeks.

Gut bacteria can turn carnitine into trimethylamine N-oxide (TMAO), a substance linked to heart disease, more so in people who eat meat. The National Institutes of Health says what this means for supplement users is not yet clear; that research used L-carnitine, not ALCAR.

The science behind acetyl-L-carnitine

The clearest contrast is less pain in some diabetic-neuropathy trials and worse neuropathy during taxane chemotherapy. Mood, memory and fatigue need separate answers because the trials enrolled different people and measured different outcomes.

Diabetic nerve damage

In 2005, two year-long trials with 1,257 people with diabetic nerve damage compared 500 or 1,000 mg three times a day with placebo. Vibration sense and counts of regrowing nerve fibers in biopsy samples improved, while nerve-conduction tests did not. Pain improved in one study and in the pooled group taking 1,000 mg three times a day. The tissue samples therefore showed more regrowing fibers without an improvement in how fast and strongly nerves carried signals. Two authors worked for Sigma-Tau, the company that made the product.

The daily totals were 1.5 or 3 g (1,500 or 3,000 mg). The combined analysis did not establish that 3 g worked better than 1.5 g.

A 2019 review combined four trials in diabetic and HIV-treatment-related nerve pain. The percentage reduction from each person’s starting pain score was about 20 percentage points greater with ALCAR than with placebo; two review authors disclosed relationships with Sigma-Tau or Alfasigma. A 2016 trial compared ALCAR with methylcobalamin, a form of vitamin B12, but had no placebo group. Liaoning Haisike Pharmaceutical supplied both treatments. What is still open is whether the diabetic nerve-pain benefit holds in an independent trial.

Chemotherapy nerve damage

A trial run through a U.S. cancer research network gave 409 women receiving taxane chemotherapy 1,000 mg three times a day or a placebo for 24 weeks. Nerve damage was worse on ALCAR, most clearly from 24 to 52 weeks. At 104 weeks, the separate between-group comparison did not show a clear difference, although the analysis combining all follow-up visits found worse scores on average with ALCAR. A 2023 review of three trials agreed: no prevention at 12 weeks, more nerve damage at 24 weeks.

Depression: a positive signal with uneven support

The strongest reason to investigate ALCAR for mood comes from small clinical trials in people with depression, particularly older adults. The 2018 Veronese review^[4] included 12 trials and 791 participants. Nine trials compared it with placebo or no intervention; three compared it with antidepressant medicines.

The placebo/no-intervention comparison favored ALCAR on depressive-symptom scores, but results differed markedly between studies. The three drug comparisons found no clear difference in symptom improvement and reported fewer adverse effects with ALCAR. That does not establish that the treatments are interchangeable: a small comparison can fail to detect a meaningful difference.

The 2026 Kumar review^[5] overlaps this older evidence. Its main analysis of ten randomized trials also favored treatment, with very large differences between study results and signs that smaller studies gave a different impression from larger ones. It covered treatment courses of roughly six to twelve weeks, generally using 1–3 g/day. Older-adult studies had a stronger signal than younger-adult studies; the younger group and the analysis of adding treatment to an existing medicine did not show a clear benefit.

There is an additional complication: the newer review includes combination products and describes a 2022 trial as acetyl-L-carnitine even though the original paper identifies L-carnitine^[6]. That study added 1,000 mg/day L-carnitine to sertraline for six weeks and found no significant advantage. It cannot be treated as a clean test of ALCAR. The newer pooled estimate therefore needs more checking before it can quantify an ALCAR-only benefit.

ALCAR is worth further research for depression, but the evidence does not support replacing prescribed treatment or promising that adding it will help. A positive average across unlike studies leaves substantial uncertainty about which patients benefit.

Memory and dementia: why the early signals were not enough

The updated Cochrane dementia review^[7] explains why older positive findings have not translated into routine use. It assessed randomized trials in people with dementia or cognitive impairment, generally using 1–3 g/day for 12–52 weeks.

Some results favored ALCAR at earlier visits. A clinician-rated measure of improvement favored treatment at 12 and 24 weeks, but not at 52 weeks. On the Mini-Mental State Examination, a 30-point screening test, the pooled difference at 24 weeks was about 0.7 points, with an uncertainty range of roughly 0.1–1.3 points. There was no significant advantage on that test at 12 or 52 weeks. Measures of functional ability and dementia severity did not show a benefit.

The reviewers emphasized the many comparisons and lack of consistent effects across outcomes and time points, and did not recommend routine clinical use. Some short-term scores improved, but the pattern was too inconsistent to establish useful, lasting dementia treatment. These trials also do not answer whether a healthy adult becomes more productive or learns faster.

Fatigue in multiple sclerosis: a small comparison with another medicine

In Tomassini's 2004 pilot^[8], 36 people with multiple sclerosis and fatigue entered a randomized, double-blind crossover study. The study compared two treatments for fatigue: ALCAR 1 g twice daily and the medicine amantadine 100 mg twice daily. Participants took one treatment for three months, then switched to the other after a three-month break between treatments.

The primary Fatigue Severity Scale comparison favored ALCAR. Six participants withdrew because of adverse reactions: five during amantadine and one during ALCAR. However, the secondary measures of fatigue's impact, depression and social experience did not significantly improve. The abstract does not give the size of the primary score difference.

This suggests a possible role in MS-related fatigue, with better tolerability than amantadine in this small experiment. There was no placebo period, so it does not establish how much either treatment helped compared with taking neither. The result belongs in a discussion of MS fatigue with the treating clinician, rather than a general energy claim.

Fatigue in older adults: a separate, unfinished question

Malaguarnera's 2008 study^[9] investigated 96 adults over 70 with persistent fatigue. The abstract reports favorable between-group changes in physical and mental fatigue, fatigue severity and function. This is relevant evidence for older adults with substantial symptoms, distinct from the MS trial.

The accessible abstract does not identify the dose, treatment duration or comparison treatment. Those details matter enough that we cannot turn its positive results into a particular supplement regimen here. The full report still needs checking. It is a promising lead, with the practical question unresolved.

Neither fatigue study tested an immediate boost before work or exercise in healthy adults. Carnitine's role in energy metabolism explains why fatigue is investigated; whether additional ALCAR helps depends on the clinical setting.

Male infertility: sperm movement and pregnancy are different outcomes

A 2005 trial^[10] assigned 60 infertile men with poor sperm movement to 3 g/day acetyl-L-carnitine, 3 g/day L-carnitine, a combination of 2 g L-carnitine plus 1 g acetyl-L-carnitine, or placebo for six months; 59 completed it. The authors reported improved sperm movement with acetyl-L-carnitine alone and with the combination, especially among men starting with worse measurements. The abstract does not provide the size and uncertainty of each active-versus-placebo difference.

An earlier six-month trial^[11] studied the same 2 g plus 1 g combination against placebo in 60 infertile men; 56 completed it. Again, the strongest sperm-movement findings were in men with worse starting measurements. These are early findings about semen quality. They do not establish that acetyl-L-carnitine alone increases pregnancy or live-birth rates, and results from L-carnitine alone or mixtures should not be assigned to every ALCAR capsule.

The bottom line

Acetyl-L-carnitine trials found some relief in diabetic nerve pain, while nerve-conduction tests did not improve. Short-term memory-score changes have not established lasting dementia benefit. Mood studies suggest a possible benefit, especially in older adults, but do not establish a dependable add-on effect or equivalence to antidepressants. Small fatigue trials offer leads in multiple sclerosis and older adults with persistent symptoms; they do not yet supply a general energy recommendation.

The chemotherapy finding changes the decision completely: it worsened nerve damage during taxane treatment. We would not choose it as a general nerve-protection supplement. The reason for taking it and the treatment you are already receiving matter more than the fact that the body uses carnitine for energy.